Madelaine Kuiper, MSN, NP, Discusses Rapid Development of HER2-Targeted Therapies

Madelaine Kuiper, MSN, NP, from UCLA Health, discussed the progression of HER2-positive breast cancer treatment at the San Antonio Breast Cancer Symposium, held December 10-14, in San Antonio, Texas.

Transcription:
You know look, honestly, from determining when Dr. Slamon first developed HER2 notification or amplification and then developing trastuzumab (Herceptin) to manage this disease, I mean it’s changed rapidly. I have to say, I do remember in the 80s when he was working on this stuff and when we were actually treating patients once approved, but even in the last, gosh, you know the last 6 years that I’ve been working with breast particularly, is the rapid development of HER2 targeted therapies, you know, with the development of trastuzumab emtansine (T-DM1) and then pertuzumab (Perjeta) and then the oral tucatinib, and now some of the later stuff with DS-8201 (trasuzumab deruxtecan), I mean it’s just amazing how many drugs are looking very positive in this setting and expanding treatment options for patients definitely.